Rather than chasing a changing virus, biochemist Tyler Starr and collaborators are developing an antibody that can tolerate variation in its target, with potential to bind SARS-CoV-2 and dozens of related viruses: https://utah-health.shorthandstories.com/ptf-better-outcomes-for-patients/
